CMS Reverses Biosimilars-Pay Policy That Would Have Lowered Prices

CMS on Thursday (Nov. 2) reversed a policy meant to drive down biosimilars prices -- a reversal that drug makers say overall will save Medicare money but that nonpartisan congressional Medicare advisers say will lead to both higher biosimilars prices and an increase in Medicare spending. About a month ago, several drug company executives and lobbyists met with White House officials to lobby against the Obama-era policy that CMS reversed. “As part of the President’s priority to reduce drug costs...